Key result
Impella CP support enables survival and full LVEF recovery to ~55% in fulminant myocarditis.
Case Report (n=1)
No
Demonstrates that severe myocardial failure and cardiogenic shock due to biopsy-proven fulminant myocarditis can be fully reversible when bridged with temporary Impella CP mechanical circulatory support.
Answers are grounded in this paper and cite their sources.
May support Impella bridging in select fulminant myocarditis; hypothesis-generating and should not yet change practice.
BACKGROUND: Treating myocarditis can be difficult, as clear criteria for diagnosis and management are lacking for heterogeneous clinical presentations. CASE DESCRIPTION: We report a case of a 49-year-old female who presented with cardiogenic shock and subsequent cardiac arrest. Extracorporeal life support was instituted, and after eight days with Impella CP the patient recovered and at six months presented with normal cardiac function. CONCLUSION: Fulminant myocarditis remains a challenging disease in daily clinical practice, not only for diagnosis, but also for treatment. With this report we emphasize that myocardial failure due to fulminant myocarditis may be reversible if treated with extracorporeal life support, which thus plays an important and life-saving role.
No takes yet. Share an insight, caveat, or question.
Fox et al. (2017) conducted a case report in Fulminant myocarditis with cardiogenic shock and cardiac arrest (n=1). Impella CP extracorporeal life support was evaluated on Recovery of left ventricular ejection fraction (LVEF) and survival at 6 months. Impella CP support for 8 days in a 49-year-old female with fulminant myocarditis and cardiogenic shock resulted in survival and LVEF recovery from 10% to 55% at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: